Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 05, 2023 08:30 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Establishes Research Collaboration With University College London to Study the Use of AMPAkines for the Treatment of GRIA Disorders

Glen Rock, N.J., April 05, 2023 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
May 12, 2021 09:15 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces New Data Regarding the Use of AMPAkines as Potential Treatments for Spinal Cord Injury

Glen Rock, N.J., May 12, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
April 22, 2021 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Provides Update on Its Development Programs

Glen Rock, N.J., April 22, 2021 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the discovery and development of innovative and...
February 03, 2020 09:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Announces Appointment of Tim Jones to its Board of Directors

Glen Rock, N.J, Feb. 03, 2020 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTCQB: RSPI) (“RespireRx” or the “Company”), a leader in the research and development of cannabinoids for the...
January 08, 2018 08:45 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. to Present at 10th Annual Biotech Showcase™ 2018

CEO to Review completed Phase IIB dronabinol trial for the treatment of Obstructive Sleep Apnea (OSA) and Provide Pipeline update Glen Rock, N.J., Jan. 08, 2018 (GLOBE NEWSWIRE) -- RespireRx...
December 15, 2017 09:00 ET | Source: RespireRX Pharmaceuticals Inc.

RespireRx Pharmaceuticals Inc. Officers and Directors Elect to Forgive $2,356,733 of Past Due Cash Compensation and Receive Non-Qualified Stock Options to Reduce Balance Sheet Debt

Glen Rock, N.J., Dec. 15, 2017 (GLOBE NEWSWIRE) -- RespireRx Pharmaceuticals Inc. (OTC QB: RSPI) (“RespireRx” or the “Company”), a leader in the development of medicines for the treatment of...
May 14, 2015 07:00 ET | Source: Akers Biosciences Inc.

Financial Results for First Quarter 2015

THOROFARE, N.J., May 14, 2015 (GLOBE NEWSWIRE) -- Akers Biosciences, Inc. (Nasdaq:AKER) (AIM:AKR.L) (the "Company" or "Akers Bio"), a medical device company focused on reducing the cost of healthcare...